T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion
Open Access
- 16 July 2003
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 43 (2) , 122-130
- https://doi.org/10.1093/rheumatology/keg447
Abstract
Erosion of periarticular bone is a hallmark of rheumatoid arthritis (RA), resulting in significant joint deformity, pain and disability [1]. Osteoclasts are specialized cells of the macrophage lineage responsible for bone resorption during remodelling. These cells have been demonstrated at the site of erosion in RA [2, 3] and in representative animal models of the disease [4], and are thus believed to be critical in the pathogenesis of joint damage. Developments in research methods have facilitated significant advances in the understanding of osteoclast regulation in conditions characterized by excessive bone resorption, including RA. As the osteoblast-derived signal that regulates osteoclasts [receptor activator of nuclear factor κB ligand (RANKL); see below] is identical to TRANCE (tumour necrosis factor-related activation-induced cytokine), which was first discovered in studies of T cells [5, 6], the intriguing role of T cells in bone biology has generated a considerable literature, referred to as ‘osteoimmunology’ [7]. In this article we will briefly describe normal bone remodelling and RANKL expression by T cells in the interaction with dendritic cells (DCs). Osteoclast regulation by T-cell expression of RANKL and other cytokines will then be described in the setting of the three clinical conditions most commonly studied—RA and its animal models, osteoporosis, and adult periodontitis. Potential therapeutic strategies for the prevention of bone loss in RA will be highlighted.Keywords
This publication has 103 references indexed in Scilit:
- Transforming growth factor-β1 (TGF-β) stimulates the osteoclast-forming potential of peripheral blood hematopoietic precursors in a lymphocyte-rich microenvironmentBone, 2001
- The combination of tumor necrosis factor ? blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo modelArthritis & Rheumatism, 2001
- Parathyroid Hormone-induced Bone Resorption Does Not Occur in the Absence of OsteopontinPublished by Elsevier ,2001
- Proposed Standard Nomenclature for New Tumor Necrosis Factor Family Members Involved in the Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Activated T Lymphocytes Support Osteoclast Formation in VitroBiochemical and Biophysical Research Communications, 1999
- IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJournal of Clinical Investigation, 1999
- REGULATION OF IMMUNE RESPONSES BY TGF-βAnnual Review of Immunology, 1998
- A New Mechanism of Bone Destruction in Rheumatoid Arthritis: Synovial Fibroblasts Induce OsteoclastogenesisBiochemical and Biophysical Research Communications, 1997
- The Emerging Role of CTLA-4 as an Immune AttenuatorImmunity, 1997
- Suggested Sequential Mode of Control of Changes in Cell Behaviour in Adult Bone RemodellingNature, 1965